AEGON ASSET MANAGEMENT UK Plc Takes Position in Biogen Inc. $BIIB

AEGON ASSET MANAGEMENT UK Plc bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 195,635 shares of the biotechnology company’s stock, valued at approximately $27,399,000. AEGON ASSET MANAGEMENT UK Plc owned about 0.13% of Biogen as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Empowered Funds LLC boosted its holdings in shares of Biogen by 64.9% during the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after acquiring an additional 2,777 shares during the period. Focus Partners Wealth lifted its holdings in Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after purchasing an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Biogen in the 2nd quarter valued at $216,000. Park Avenue Securities LLC boosted its stake in Biogen by 4.5% in the 2nd quarter. Park Avenue Securities LLC now owns 3,203 shares of the biotechnology company’s stock valued at $402,000 after purchasing an additional 137 shares during the period. Finally, Fifth Third Bancorp grew its holdings in Biogen by 34.4% in the 2nd quarter. Fifth Third Bancorp now owns 7,377 shares of the biotechnology company’s stock valued at $926,000 after buying an additional 1,888 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on BIIB shares. Mizuho boosted their target price on shares of Biogen from $177.00 to $207.00 and gave the company an “outperform” rating in a research report on Thursday, January 8th. Citigroup lifted their price objective on shares of Biogen from $153.00 to $180.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 7th. Sanford C. Bernstein increased their target price on shares of Biogen from $157.00 to $197.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. BMO Capital Markets lifted their price target on shares of Biogen from $150.00 to $165.00 and gave the company a “market perform” rating in a research report on Thursday, December 18th. Finally, Jefferies Financial Group increased their price target on Biogen from $190.00 to $210.00 and gave the stock a “buy” rating in a research report on Friday, November 28th. Ten equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $191.85.

Biogen Trading Down 1.3%

Shares of BIIB opened at $171.59 on Monday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.04 and a current ratio of 2.72. Biogen Inc. has a 52-week low of $110.04 and a 52-week high of $190.20. The firm has a market cap of $25.17 billion, a price-to-earnings ratio of 15.64, a PEG ratio of 1.43 and a beta of 0.13. The business’s fifty day moving average is $175.80 and its 200-day moving average is $153.45.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share for the quarter, topping the consensus estimate of $3.89 by $0.92. The business had revenue of $2.53 billion during the quarter, compared to the consensus estimate of $2.34 billion. Biogen had a return on equity of 14.13% and a net margin of 15.98%.Biogen’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the prior year, the company earned $4.08 EPS. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Equities analysts anticipate that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.